Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asterias Biotherapeutics Inc.

Division of BioTime Inc.
www.asteriasbiotherapeutics.com

Latest From Asterias Biotherapeutics Inc.

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deals Business Strategies

Novo Nordisk Ups Lay Offs In R&D Push; Preps UK Supply Chain For Hard Brexit

Novo Nordisk's decision to free up resources for R&D investment means 1,300 lay-offs across the company by the end of the year. The Danish group is meanwhile stockpiling medicines and bolstering its supply chain outside the UK in case of  a 'no deal' hard Brexit, its CEO says.

Brexit Business Strategies

Novo Nordisk CSO Says R&D Revamp Reflects New Stem Cell And AI Focus

Mads Krogsgaard Thomsen tells Scrip that recent successes in stem cell research and the on-going advances in artificial intelligence helped prompt the Danish group to revamp its R&D activities.

Business Strategies Commercial

Pipeline Watch: Phase III Starts With Bavencio, MultiStem And VT-1161

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Neurology, Nervous System
  • Alias(es)
  • BioTime Acquisition Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BioTime Inc.
  • Senior Management
  • Michael L Mulroy, CEO
    Ryan Chavez, CFO
    Edward D Wirth, III, MD, PhD, CMO
    Craig Halberstadt, PhD, SVP, Research & Product Dev.
  • Contact Info
  • Asterias Biotherapeutics Inc.
    Phone: (510) 456-3800
    6300 Dumbarton Circle
    Fremont, CA 94555
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register